Neuropilin-1: Potential Therapeutic & Biomarker (G8829)

Target Name: NRP1

NCBI ID: G8829

NRP1

Neuropilin-1: Potential Therapeutic & Biomarker

Neuropilin-1 (NP-1) is a protein that is expressed in various tissues throughout the body, including the brain. It is a member of the neuropilin family, which is a family of transmembrane proteins that play a critical role in the development and maintenance of neural networks.

NP-1 has been shown to be involved in a number of different processes in the brain, including the regulation of ion channels, neurotransmitter release, and cell survival. It is also known to be involved in the development and progression of a number of neurological disorders, including Alzheimer's disease and Parkinson's disease.

In recent years, researchers have been interested in investigating the potential therapeutic benefits of targeting NP-1. One approach that has been explored is the use of small molecules that can modulate NP-1 activity. These small molecules are called \"inhibitors\" because they work to reduce the activity of NP-1.

One of the most promising inhibitors of NP-1 is called \"NP-1-specific\" because it is designed to specifically target the protein. This inhibitor has been shown to be effective in animal models of Alzheimer's disease, and it is now being tested in clinical trials.

Another approach that is being explored is the use of RNA interference (RNAi) to knock down the expression of NP-1. This is a technique that involves using small interfering RNA (siRNA) to reduce the amount of a specific protein that is expressed in the cell.

RNAi has been shown to be an effective way to knock down the expression of NP-1, and it is being used to treat a number of different diseases, including Alzheimer's disease and Parkinson's disease.

In addition to its potential therapeutic benefits, NP-1 is also being investigated as a potential biomarker. This is because it is expressed in a number of different tissues and cells, including the brain, and it can be used as a target for studying the effects of different therapies.

One way that researchers are using NP-1 as a biomarker is by using techniques such as immunohistochemistry and Western blotting to detect the expression of NP-1 in different tissues and cells. This has allowed researchers to study the effects of different therapies on the expression of NP-1 and to gain insights into the underlying mechanisms of these therapies.

Overall, NP-1 is a protein that is involved in a number of different processes in the brain, and it has the potential to be a drug target or biomarker. Further research is needed to fully understand its role in neural networks and to develop effective therapies that can target it.

Protein Name: Neuropilin 1

Functions: Cell-surface receptor involved in the development of the cardiovascular system, in angiogenesis, in the formation of certain neuronal circuits and in organogenesis outside the nervous system. Mediates the chemorepulsant activity of semaphorins (PubMed:9288753, PubMed:9529250, PubMed:10688880). Recognizes a C-end rule (CendR) motif R/KXXR/K on its ligands which causes cellular internalization and vascular leakage (PubMed:19805273). It binds to semaphorin 3A, the PLGF-2 isoform of PGF, the VEGF165 isoform of VEGFA and VEGFB (PubMed:9288753, PubMed:9529250, PubMed:10688880, PubMed:19805273). Coexpression with KDR results in increased VEGF165 binding to KDR as well as increased chemotaxis. Regulates VEGF-induced angiogenesis. Binding to VEGFA initiates a signaling pathway needed for motor neuron axon guidance and cell body migration, including for the caudal migration of facial motor neurons from rhombomere 4 to rhombomere 6 during embryonic development (By similarity). Regulates mitochondrial iron transport via interaction with ABCB8/MITOSUR (PubMed:30623799)

The "NRP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NRP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets